DVAX - Dynavax Technologies Corporation
| Previous Close | 6.35 |
| Open | 6.44 |
| Bid | 5.56 x 4000 |
| Ask | 5.86 x 800 |
| Day's Range | 5.12 - 6.91 |
| 52 Week Range | 5.12 - 17.05 |
| Volume | 5,270,363 |
| Avg. Volume | 1,226,312 |
| Market Cap | 376.087M |
| Beta (3Y Monthly) | 0.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.54 |
| Earnings Date | Aug 5, 2019 - Aug 9, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.75 |
- Motley Fool•2 days ago
Here's Why Dynavax Technologies Is Tumbling
The company's latest restructuring announcement isn't sitting well with investors.
- American City Business Journals•2 days ago
East Bay biotech pivoted to cancer, found new space — now CEO is leaving, 82 jobs are cut
The company is returning its focus to its easier-to-take hepatitis B vaccine and other vaccine work.
- Benzinga•2 days ago
The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
- MarketWatch•3 days ago
Dynavax announces layoffs, CEO retirement
Dynavax Technologies Corp. said late Thursday it will focus on its vaccine business and on its first commercial product, a hepatitis B vaccine, looking to unwind its immuno-oncology business. The company will also lay off workers and trim operations to focus on the vaccine's commercialization. "Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B, which, as the only two-dose hepatitis B vaccine, is gaining market share and is well positioned to become the new standard of care in the U.S," Chief Executive Eddie Gray said. In the same press release, Gray said that the restructuring was "the optimal time" for his retirement, effective Aug. 1. The company's board of directors has created an interim office of the president and has appointed David Novack and Ryan Spencer, two senior vice presidents, as co-presidents effective immediately. Shares of Dynavax, halted earlier in the extended session, fell more than 5% when they resumed trading. The shares ended the regular session 0.2% lower.
- GlobeNewswire•3 days ago
Dynavax Announces Strategic Restructuring to Focus on its Vaccine Business
Dynavax Technologies Corporation (DVAX), today announced a strategic restructuring to prioritize its vaccine business by focusing on the company’s first commercial product HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]. As part of the restructuring, the company will explore strategic alternatives for its immuno-oncology portfolio and will reduce the company’s workforce and operations to focus resources on HEPLISAV-B commercialization.
- Simply Wall St.•5 days ago
Could The Dynavax Technologies Corporation (NASDAQ:DVAX) Ownership Structure Tell Us Something Useful?
The big shareholder groups in Dynavax Technologies Corporation (NASDAQ:DVAX) have power over the company. Large...
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of DVAX earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Dynavax Technologies Corp Earnings Call
- TheStreet.com•16 days ago
Hopeful Signs for These 2 Small Biotech Stocks
A non-biotech investor would think FDA approval is the biggest hurdle for most small biotech companies and would be rewarded by the market. This is why so many small biotech stocks frequently decline in the quarters following the initial euphoria of FDA approval. This is why initial drug rollouts are usually slower and consume more cash that investors expect after the FDA green light is granted.
- Motley Fool•17 days ago
Why Dynavax Technologies Stock Is Soaring Today
Heplisav-B's commercial launch is starting to ramp up.
- Insider Monkey•17 days ago
Is Dynavax Technologies Corporation (DVAX) A Good Stock To Buy?
How do we determine whether Dynavax Technologies Corporation (NASDAQ:DVAX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
Motley Fool•18 days agoDynavax Technologies Corp (DVAX) Q1 2019 Earnings Call Transcript
DVAX earnings call for the period ending March 31, 2019.
- Zacks•18 days ago
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 7.46% and -3.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 days ago
Dynavax Technologies: 1Q Earnings Snapshot
The Berkeley, California-based company said it had a loss of 62 cents per share. The biopharmaceutical company posted revenue of $5.8 million in the period. Dynavax Technologies shares have fallen 29% ...
- GlobeNewswire•18 days ago
Dynavax Announces First Quarter 2019 Financial Results
First quarter 2019 HEPLISAV-B® net product revenue of $5.6 millionConference call to be held today at 4:30 p.m. ET/1:30 p.m. PT BERKELEY, Calif., May 08, 2019 -- Dynavax.
- ACCESSWIRE•18 days ago
Dynavax Technologies Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Dynavax Technologies Corp. (NASDAQ: DVAX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 4:30 PM ...
- GlobeNewswire•24 days ago
Dynavax Announces First Patient Enrolled in Study of HEPLISAV-B® in Adults With End-Stage Renal Disease
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines and immuno-oncology therapeutics, today announced the enrollment of the first patient in the company’s open-label, single-arm study of HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis. “Although vaccination to prevent hepatitis B infection has been standard practice for decades for dialysis patients and healthcare workers, there remains a need to provide improved overall protection safely through a greater and more durable antibody response,” said Robert Janssen, M.D., chief medical officer of Dynavax. This open-label, single arm study will evaluate HEPLISAV-B in adults with end-stage renal disease who are initiating or undergoing hemodialysis.
- Zacks•25 days ago
Analysts Estimate Dynavax Technologies (DVAX) to Report a Decline in Earnings: What to Look Out for
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•last month
Dynavax Technologies to Report First Quarter 2019 Financial Results and Host Conference Call on May 8
BERKELEY, Calif., April 25, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
- GlobeNewswire•last month
Dynavax to Present Data on Toll-like Receptor 9 Agonist SD-101 at the ASCO Annual Meeting 2019
BERKELEY, Calif., April 18, 2019 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel.
- Simply Wall St.•2 months ago
Investors Who Bought Dynavax Technologies (NASDAQ:DVAX) Shares Three Years Ago Are Now Down 66%
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But l...
- American City Business Journals•2 months ago
After inking lease with cancer-fighting company, this new East Bay biotech project is full
EmeryStation West is the latest building in Wareham Development's 2 million-square-foot complex in Emeryville.
- GlobeNewswire•2 months ago
Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced results from the ongoing Phase 1b clinical study evaluating the safety of DV281, a novel toll-like receptor (TLR) 9 agonist in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer (NSCLC). The results were presented today in a poster session at the 2019 American Association for Cancer Research (AACR) Annual Meeting 2019 (Exhibit Hall B, Poster Section 17, Poster Board Number: #18, 1:00 pm. – 5:00 p.m. ET).
- Benzinga•2 months ago
The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- GlobeNewswire•2 months ago
Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults
Dynavax Technologies Corporation (DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has accepted the Company's Marketing Authorization Application (MAA) for review of HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. This acceptance follows Dynavax's submission of the MAA on March 11 and marks the beginning of the regulatory review process for HEPLISAV-B in the European Union (EU). The outcome of the MAA review by the EMA is expected next year.
- CNW Group•2 months ago
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
